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The corticotrophin-releasing hormone-proopiomelano-
cortin (CRH-POMC) system in the skin coordinates 
pigmentation and the immune response. The aim of this 
study was to evaluate the regulatory role of the neuro-
endocrine system in the pathogenesis of psoriasis. Using 
quantitative real-time-PCR, mRNA expression levels of 
15 genes related to the CRH-POMC system were mea-
sured in punch biopsies from lesional and non-lesional 
skin of patients with psoriasis and from skin of healthy 
control subjects. Statistically significant up-regulation 
of POMC, CRH receptor type 1, melanin-concentrating 
hormone receptor (MCHR1) and melanocortin receptors 
2, 3 and 4 mRNA expression in lesional and in non-lesi-
onal skin compared with healthy control samples were 
established. Tyrosinase (TYR), T(Y)RP-1 and ASIP genes 
were statistically significantly down-regulated in lesio-
nal and non-lesional skin of psoriasis samples compared 
with healthy subjects. The up-regulation of POMC, me-
lanocortin receptors, CRH receptor type 1 and MCHR1 
in the lesional and non-lesional skin of psoriasis patients 
supports the importance of the local CRH-POMC sys-
tem in the pathogenesis of psoriasis. Key words: psoriasis; 
CRH-POMC system; mRNA expression.
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The central nervous system (CNS) regulates inflamma-
tory responses through hormonal and neuronal routes. 
The neuroendocrine stress response (the hypothalamic-
pituitary-adrenal (HPA) axis) and the sympathetic and 
parasympathetic nervous systems generally inhibit in-
flammation at the systemic and regional levels, whereas 
the peripheral nervous system tends to amplify local 
inflammatory responses (1). A blunted neural regulation 
is seen in a wide range of autoimmune and inflamma-
tory diseases in humans, such as rheumatoid arthritis, 
Sjögren’s syndrome, systemic lupus erythematosus and 
irritable bowel syndrome (2, 3).
The presence of cutaneous corticotrophin-releasing 
hormone (CRH) peptide and corticotrophin-releasing 
hormone receptor (CRH receptor type 1 and 2 (CRH-
R1 and CRH-R2)) peptides, which are the binding site 
for CRH and the related urocortin peptide, suggests a 
potential CRH-induced neuroendocrine pathway in the 
skin (4, 5). Cutaneous expression of the CRH-proopio-
melanocortin (CRH-POMC) system is highly organized, 
encoding mediators and receptors similar to the HPA 
axis (5, 6) including key enzymes of corticosteroid and 
glucocorticoid synthesis (6). CRH stimulates CRH-R1 
and induces the production and secretion of POMC (7). 
In melanocytes and fibroblasts CRH-induced CRH-R1 
stimulation upregulates POMC expression and produc-
tion of adrenocorticotropic hormone (ACTH) through 
the activation of cAMP-dependent pathway(s). Melano-
cytes respond with enhanced production of cortisol and 
corticosterone, which is dependent on POMC activity. 
Fibroblasts respond to CRH and ACTH with enhanced 
production of corticosterone, but not cortisol, which is 
produced constitutively (6). The POMC system consists 
of the melanocortin peptides α-, β-, and γ-melanocyte 
stimulating hormone (α-, β-, γ-MSH) and ACTH, which 
derive from post-translational processing of the precur-
sor molecule proopiomelanocortin (POMC); a family 
of 5 melanocortin receptors (MCRs); 2 endogenous 
melanocortin receptor antagonists: agouti (ASIP) and 
agouti-related protein (AGRP) (8). The CRH-POMC 
system in the skin primarily coordinates pigmentation 
and the immune response (4, 5).
The expression of the components of the CRH-POMC 
system in the skin has been detected in different cell 
types. In the skin CRH mRNA expression has been de-
monstrated in cultured melanocytes and keratinocytes 
(5). In humans, CRH-R1 is predominantly expressed 
in all major skin cell populations (9), while CRH-R2 is 
expressed in dermal cells including hair follicle kerati-
nocytes, melanocytes and follicular papilla fibroblasts, 
sebaceous and eccrine glands, muscle and dermal blood 
vessels (10). CRH-R1 mediates most phenotypic effects 
of CRH, while the main adnexal location of CRH-R2 
indicates a role for this receptor in hair cycling (9). The 
POMC gene is expressed by cutaneous keratinocytes 
and melanocytes (8). In the skin the highest expression 
of MC1R mRNA expression has been detected in mela-
nocytes (11). Human MC1R has the highest, and almost 
equal, affinity for α-MSH and ACTH, less affinity for 
β-MSH, and least affinity for γ-MSH (12). MC2R is 
the classical adrenocortical ACTH receptor (8) and its 
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expression has been detected in keratinocytes (13) and 
adipocytes (14). MC3R expression in the skin has been 
shown in our previous studies, although its expression 
has not been localized to distinct cell types (15). All of 
the melanocortins are roughly equipotent with MC3R 
(8). MC4R is expressed in dermal papilla cells (16) and 
melanocytes (17), and is activated by α-MSH and ACTH 
(8). The expression of MC5R has been detected in skin 
mast cells, adipocytes and sebocytes (5, 18). Its affinity 
for POMC peptides is similar to that of MC1R (8). 
Tyrosinase (TYR) is regarded as the key enzyme in me-
lanogenesis; it is found in melanosomes (19). Tyrosinase-
related protein 1 (TYRP1) and dopachrome tautomerase 
(DCT) are additional melanogenesis enzymes. The signal 
from the CRH-POMC system in human melanocytes 
reaches the melanogenesis enzymes TYR, TYRP1 
and DCT over MC1R through cyclic adenosine mono-
phosphate/protein kinase A (cAMP/PKA) pathway and 
it is modulated by Wnt and MAPK (mitogen-activated 
protein kinase) pathways (17, 20). ASIP is an antagonist 
of human MC1R. It acts as a competitive inhibitor of 
α-MSH and inhibits the expression of the melanogenic 
enzymes tyrosinase, TYRP-1, and DCT (21).
In cultured human melanocytes the melanogenic 
actions of α-MSH were inhibited by melanin-concen-
trating hormone (MCH), resulting in reduced melanin 
production in pigment cells. Such evidence suggests that 
one of the roles of MCH/MCH-R1 in the skin could be 
in regulating pigmentation by opposing the actions of 
the melanocortin system (22). MCH is produced from 
pro-melanin-concentrating hormone (PMCH). In the 
human skin the expression of PMCH has been detected 
in cultured endothelial cells, whereas no signal has been 
found in keratinocytes, melanocytes and fibroblasts. 
MCHR1 expression has been demonstrated in melano-
cytes and melanoma cells (23). 
The abnormal expression of CRH-POMC system pep-
tides has been described in a number of skin conditions, 
such as neoplastic melanocytic naevi, melanoma, basal 
cell carcinoma, squamous cell carcinoma, inflammatory 
keloids, and scarring alopecia (11). Our study group has 
previously demonstrated abnormal gene expression of 
the melanocortin system in vitiligo skin samples com-
pared with healthy control skin (15). The importance of 
CRH-POMC system in the pathogenesis of psoriasis is 
supported by exacerbation and triggering of the disease 
due to emotional stress and local trauma (24–29). Hea-
ling of the psoriatic lesions with temporary hyper- or 
hypo-pigmentation also implicates the involvement of 
the CRH-POMC system in the pathogenesis of psoriasis. 
Until now there have been only a few limited studies that 
have analysed gene expression levels of CRH-POMC 
system in psoriasis skin samples. 
The aim of the present study was to explore the re-
gulation of the cutaneous stress system in psoriasis by 
examining the expression variations of genes encoding 
mediators of the CRH-POMC system and melanogene-
sis enzymes in lesional and non-lesional psoriasis skin 
and in the skin of healthy controls.
MATERIALS AND METHODS
The protocols and informed consent forms for this study were 
approved by the ethics Review Committee on Human Research 
of the University of Tartu. All of the participants signed a writ-
ten informed consent.
Patients and healthy controls
The patients and control subjects in the study were Caucasi-
ans living in Estonia. Twenty (2 females; 18 males) unrelated 
patients with plaque-psoriasis, mean age 40.85 years (range 
18–64 years) were recruited from the outpatient as well as 
from the inpatient clinic at the Department of Dermatology, 
Tartu University Hospital. The mean age of psoriasis onset of 
the patients was 28.4 years. The Psoriasis Area Severity Index 
(PASI) score was recorded by the same physician in all cases. 
The mean PASI score was 25.05 (range 7–69). One patient had 
PASI less than 7 (mild disease) and all others had PASI over 7 
(moderate and severe disease). Ten of the patients had psoriatic 
nail involvement, 3 had psoriatic arthropathy, and 7 patients 
had a positive family history of psoriasis. The biopsies were 
taken from non-sun-exposed areas. Prior to taking the biopsies 
the patients’ group had not received any treatment, including 
ultraviolet B (UVB)-therapy, local corticosteroids and syste-
mic medication for at least a month. Healthy volunteers free 
from other dermatoses and from the positive family history of 
psoriasis, were recruited as a control group (n = 56; (18 male, 
38 female); Mean age 36.1 years (range 21–70 years). As the 
female/male ratio differs between study groups it should be 
clarified that, based on current literature, sex and age do not 
influence the mRNA expression of studied genes.
Skin samples and TaqMan-quantitative real-time-PCR
Two 4-mm punch biopsies from both involved and non-involved 
skin were obtained from each patient with psoriasis. One skin 
biopsy (diameter 4 mm) was obtained from healthy control 
subjects. All probands had skin phototype II or III, Fitzpatrick 
classification. Biopsies were instantly snap-frozen and stored 
at –80ºC until RNA extraction. 
For total RNA extraction from skin biopsies the RNeasy 
Fibrous Tissue Mini Kit (QIAGEN Sciences, Maryland, USA) 
was used according to the manufacturers’ protocol. Biopsies 
were homogenized by T 10 basic homogenizer (IKA Labor-
technik, Staufen, Germany). Extracted RNA was dissolved in 
RNase-free water and stored at –80ºC until cDNA synthesis. 
RNA quality was controlled using the NanoDrop ND 1000. For 
cDNA synthesis 250–500 ng of total RNA, oligoT18 primer and 
Superscript III reverse transcriptase (Invitrogen Corp., Carlbad, 
CA, USA) was used according to the manufacturers’ protocol. 
cDNA was used as a template for TaqMan® QRT-PCR ana-
lysis in the ABI Prism 7900HT Sequence Detection System 
(Applied Biosystems, Foster City, CA, USA). Reactions 
were carried out in 10 µl reaction volumes in 4 replicates. 
Two primers and a labelled probe were used to detect the 
mRNA expression level of the reference gene HPRT-1 (hy-
poxanthine phosphoribosyl-transferase-1) (HPRT-1 exon 
6, 5`-GACTTTGCTTTCCTTGGTCAGG-3`; HPRT-1 exon 
7, 5`-AGTCTGGCTTATATCCAACACTTCG-3`; VIC-
5`TTTCACCAAGCTTGCGACCTTGA-3`-TAMRA). The 
expression levels of POMC, MC1R, MC2R, MC3R, MC4R, 
MC5R, ASIP, TYR, T(Y)RP1, DCT, PMCH, CRH, CRHR1, 
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CRHR2 and MCHR1 were detected applying TaqMan-
QRT-PCR method using TaqMan® Gene Expression Assays 
(Applied Biosystems, Foster City, CA, USA). The assay 
mixes used were: Hs00181770_m1 (ASIP), Hs00157244_
m1 (DCT), Hs00165976_m1(TYR), Hs00167051_m1 
(TYRP1),  Hs00267168_s1 (MC1R),  Hs00265039_s1 
(MC2R),  Hs00252036_s1 (MC3R),  Hs00271877_s1 
(MC4R), Hs00271882_s1 (MC5R), Hs00174941_m1 (CRH), 
Hs01062290_m1 (CRHR1), s00266401_m1 (CRHR2), 
Hs00173595_m1 (PMCH), Hs03044476_m1 (MCHR1), 
Hs00174947_m1 (POMC). 
Statistical analysis
Comparative Ct method (ΔCt value) was used for quantification 
of mRNA, where the amount of target transcript was normalized 
according to the level of endogenous reference HPRT-1. Data for 
studied genes following normal distribution were parametrically 
tested by unpaired t-test, and data not following the normal 
distribution by Mann–Whitney U test using Graphpad Prism 4 
software (GraphPad Software, San Diego, CA, USA). For all 
tests, a p-value < 0.05 was considered significant.
RESULTS
Using the quantitative real-time (QRT)-PCR method, 
mRNA expression levels of 15 genes related to the 
CRH-POMC system were measured in punch biopsies 
from lesional and non-lesional skin of patients with 
psoriasis and from skin of healthy control subjects. 
CRH mRNA expression did not reach the detection 
threshold when 250–500 ng of cDNA was applied to the 
QRT-PCR reaction. Increased CRHR1 expression (Fig. 
1a) was found in lesional and non-lesional psoriasis skin 
compared with healthy controls. Specifically, a 3.4-fold 
increase in CRHR1 mRNA expression in involved skin 
compared with healthy subjects (p < 0.001) and 3.4-fold 
increase in CRHR1 in non-lesional skin compared with 
healthy controls (p < 0.01) was detected. 
POMC mRNA expression (Fig. 1b) in lesional skin 
of psoriasis patients was 2.8-fold higher (p < 0.001) 
compared with healthy control subjects. POMC mRNA 
expression in non-lesional skin of patients with psoriasis 
was 6.27-fold higher (p < 0.001) compared with healthy 
control subjects. 
MC1R expression level was decreased in psoriasis-
involved skin compared with uninvolved or healthy 
control skin. However, these differences were not 
statistically significant (Fig. 2, graph A). A statistically 
significant difference was found in MC2R, MC3R and 
MC4R expression (Fig. 2, graphs B, C, D) between 
healthy controls and patients with psoriasis. MC2R 
mRNA expression was 8.73-fold higher in non-lesional 
skin of psoriasis patients compared with healthy sub-
jects (p < 0.001). Likewise, the MC3R expression level 
in psoriasis non-lesional skin was 2.41-fold higher 
(p < 0.01) and the MC4R expression level was 16.4-fold 
higher (p < 0.001) than in healthy skin. In lesional skin 
a 10.1-fold increase (p < 0.001) in MC4R expression 
was detected compared with healthy control subjects. 
In psoriasis-affected skin a statistically significant 1.47-
fold increase (p < 0.001) in the expression of MC3R and 
a 3.3-fold increase in MC2R (p < 0.001) were detected 
compared with healthy control skin. MC5R mRNA 
expression levels were decreased in psoriasis lesional 
and non-lesional skin compared with healthy controls. 
The differences were not statistically significant (Fig. 
2, graph E). The expression of all MCRs is shown on a 
combined figure (Fig. 2). ASIP mRNA expression (Fig. 
3a) level in lesional skin of patients with psoriasis was 
9.8-fold lower (p < 0.001) and in psoriasis non-lesional 
skin 10.1-fold lower (p < 0.001) than in the skin of 
healthy control subjects. 
T(Y)RP1 mRNA expression (Fig. 3b) was 2-fold lower 
(p < 0.01) in psoriasis-involved skin and 1.7-fold lower 
(p < 0.05) in psoriasis non-involved skin compared with 
skin of healthy controls. TYR mRNA expression level 
(Fig. 3c) in lesional skin of psoriasis was 3.7-fold lower 
(p < 0.001) and in psoriasis non-involved skin 2.1-fold 
lower (p < 0.01) compared with healthy control subjects. 
Increased MCHR1 expression (Fig. 3d) in lesional 
and non-lesional psoriasis skin compared with healthy 
controls was established. The MCHR1 mRNA expres-
sion was 7.3-fold higher in lesional skin of patients with 
psoriasis (p < 0.001) and 8.6-fold higher in psoriasis 
non-lesional skin (p < 0.001) compared with healthy 
control subjects.
No statistically significant differences in CRHR2, 
DCT and PMCH mRNA expression were detected be-
tween any of the study groups.
a       b
Fig. 1. (a) CRHR1 mRNA and (b) POMC 
mRNA expression level in psoriasis 
lesional skin (LS). CRHR1 mRNA 
expression level was 3.4-fold higher and 
in psoriasis non-lesional skin (NLS) 3.4-
fold higher compared with healthy control 
subjects (HCS). POMC mRNA expression 
level was 2.8-fold higher and in psoriasis 
NLS 6.27-fold higher compared with HCS. 
Results are displayed as mean ± SEM. 
**p < 0.01; ***p <  0.001.
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DISCUSSION
In the present study the expression levels of genes 
related to CRH-POMC system of human skin were 
analysed: POMC, MC1R-MC5R, ASIP, CRH, CRHR1, 
CRHR2, MCHR1, PMCH; and the melanogenesis en-
zymes TYR, T(Y)RP1 and DCT.
Until now, no expression of DCT, TYR and T(Y)
RP1 mRNA has been investigated in psoriasis. In our 
previous studies of vitiligo skin samples we found de-
creased expression of DCT, TYR and T(Y)RP1 mRNA 
in vitiligo lesional skin (20, 30). In the present study 
we found statistically significant expressional down-
regulation of TYR and T(Y)RP1 mRNA, genes involved 
in melanin synthesis, in lesional and non-lesional skin of 
psoriasis patients compared with healthy controls. Even 
though DCT was down-regulated in lesional skin of 
psoriasis compared with non-lesional skin and healthy 
controls, no statistically significant differences in DCT 
mRNA expression were detected. This down-regulation 
of melanogenesis enzymes could explain why psoriatic 
lesions heal with temporary hypopigmentation.
In our study we found up-regulation of POMC mRNA 
in psoriasis lesional and non-lesional skin compared 
with healthy controls. In previous studies using im-
munohistochemical and in situ reverse-transcription 
(RT)-PCR techniques, Kono et al. (31) demonstrated 
co-expression of CRH and POMC mRNAs in the 
epidermis and pilosebaceous units of the human skin. 
Immunoreactivities and expression of CRH and POMC 
mRNAs were strong in inflammatory lesions, such 
as psoriatic and parapsoriatic lesions and other skin 
diseases. Kim et al. (32) showed in their study that 
the expression of POMC peptides ACTH and a-MSH 
was clearly stimulated in a subset of psoriasis patients 
compared with controls, but, on the whole, lacked 
 a        b






















Fig. 3. (a) ASIP mRNA, (b) T(Y)RP1 mRNA, (c) 
TYR mRNA and (d) MCHR1 mRNA expression 
level in psoriasis lesional skin (LS). ASIP mRNA 
expression level was 9.8-fold lower, and 10.1-
fold lower in psoriasis non-lesional skin (NLS) 
compared with healthy control subjects (HCS). 
T(Y)RP1 mRNA expression level was 2-fold 
lower, and 1.7-fold lower in psoriasis NLS 
compared with HCS. TYR mRNA expression 
level was 3.7-fold lower, and 2.1-fold lower in 
psoriasis NLS compared with HCS. MCHR1 
mRNA expression level was 7.3-fold higher, 
and 8.6-fold higher in psoriasis NLS compared 
with HCS. Results are displayed as mean ± SEM. 
*p < 0.05; **p < 0.01; ***p < 0.001.
Fig. 2. MC1R-MC5R mRNA expression levels in psoriasis lesional skin (LS) and in psoriasis non-lesional 
skin (NLS) compared with healthy control subjects (HCS). Results are displayed as mean ± SEM. *p < 0.05; 
**p < 0.01, ***p < 0.001. (A) MC1R mRNA expression, no statistically significant differences. (B) MC2R 
mRNA expression was 8.73-fold higher in NLS and 3.3-fold higher in LS compared with HCS. (C) MC3R 
mRNA expression level in NLS was 2.41-fold higher and in LS 1.47-fold higher compared with HCS. (D) 
MC4R mRNA expression levels in NLS skin was 16.4-fold higher and in LS 10.1-fold higher compared with 
HCS. (E) MC5R mRNA expression – no statistically significant differences.
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statistical significance. It has been shown in previous 
studies that POMC-derived peptide α-MSH has a direct 
immunoregulatory and anti-inflammatory role (33), it 
antagonizes the effects of proinflammatory cytokines, 
such as interleukin (IL)-1α, IL-1β, IL-6, and tumour-
necrosis-factor-α (TNF-α) or endotoxins, and down-
regulates the production of proinflammatory cytokines 
and accessory molecules on antigen-presenting cells, 
while production of suppressor factors, such as IL-10, 
is up-regulated by α-MSH (32). High expression of the 
proinflammatory cytokine IL-6 has been found in pso-
riatic lesional skin (34). Up-regulation of POMC mRNA 
in lesional and non-lesional psoriatic skin, established 
in the present study, may attempt to inhibit the action 
of proinflammatory factors and thereby make an effort 
to suppress inflammatory responses on the local level. 
In addition, increased levels of POMC mRNAs could, 
in some cases, explain healing of the psoriatic lesions 
with transitory hyperpigmentation.
POMC peptides exert their effects via 5 subtypes of 
MCR (32). The mRNA expression levels of the MCR 
MC2R, MC3R and MC4R were increased in lesional and 
non-lesional skin compared with healthy subjects, the dif-
ferences were statistically significant. Over-expression of 
MCR in lesional and non-lesional skin possibly indicates 
the existence of compensatory system to suppress up-
regulation of inflammatory cytokines in psoriatic lesions. 
We found statistically significant down-regulation of 
ASIP mRNA in psoriasis lesional and non-lesional skin 
compared with skin of control subjects. ASIP inhibits 
the binding of POMC derivate peptide α-MSH to MC1R 
(21). As up-regulation of POMC was found in lesional 
and non-lesional psoriatic skin, the down-regulation 
of ASIP supports our findings that the pigmentation 
of psoriasis is related to increased levels of POMC in 
the skin. This finding makes our results biologically 
meaningful and feasible.
Tagen et al. (35) found CRH-R1 mRNA expression in 
psoriasis skin to be lower than that in normal controls. 
There was no statistically significant difference in CRH-
R2 mRNA expression among the study groups. Using 
immunohistochemistry Zhou et al. (36) found that, in 
psoriatic skin, CRH/CRH-R1 expression was signifi-
cantly lower compared with a control group. Contrary 
to those results we found statistically significant in-
creases in the expression of CRHR1 mRNA in lesional 
(p < 0.001) and non-lesional (p < 0.01) psoriatic skin 
compared with healthy controls. Similarly, increased 
expression of CRHR1 has been shown in the affected 
skin of patients with other inflammatory skin diseases, 
such as contact dermatitis and chronic urticaria (33). The 
functional role of elevated CRHR1 expression in the 
skin of patients with psoriasis remains to be identified. 
There are similar changes in lesional and non-lesional 
skin compared with healthy subjects. We think that this 
is because the CRH-POMC system tries to compensate 
the inflammation in the lesional skin. The changes could 
be more marked in non-lesional skin, as the CRH-
POMC system fights inflammation more aggressively. 
The findings indicate that psoriasis involves the whole 
skin, not only the areas with visible lesions.
In conclusion, the expression of genes of the CRH-
POMC system and enzymes of melanogenesis is altered 
in psoriasis. The up-regulation of POMC, CRHR1 and 
MCHR1 in the lesional and non-lesional skin of patients 
with psoriasis supports the importance of the local 
CRH-POMC system in the pathogenesis of psoriasis. 
Up-regulation of the MCR in non-lesional and lesional 
skin and decreased expression of ASIP and enzymes 
of melanogenesis in the lesional and non-lesional skin 
probably indicates the existence of a compensatory 
system to inhibit the production of proinflammatory 
factors in the skin of patients with psoriasis. 
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